Anxiety News and Research

Latest Anxiety News and Research

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.

8 Dec 2009

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Veran Medical Technologies announced today that it received clearance (K091934) from the U.S. Food and Drug Administration (FDA) to market a product for the delivery of instruments through the pulmonary tract. "Veran is excited about this clearance as it allows the company to address a huge unmet clinical need in lung cancer diagnosis and treatment," said Jerome R. Edwards, Veran president and chief executive officer.

8 Dec 2009

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Millennium: The Takeda Oncology Company today reported the presentation of results from a double randomized Phase III clinical trial of VELCADE based combinations for the treatment of patients with previously untreated multiple myeloma (MM). The VELCADE based combinations evaluated in the study demonstrated two-year overall survival rates ranging between 81 and 88 percent.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS® System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

8 Dec 2009

New NNNS screening tool developed to identify newborn at risk

When a baby is born, new parents often wonder, "Will he be the next President of the United States?" or "Could she be the one to find a cure for cancer?" But the underlying question for many specialists is, "Is this child 'at risk' for developmental issues?"

8 Dec 2009

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

Young adults with higher blood lead levels appear more likely to have major depression and panic disorders, even if they have exposure to lead levels generally considered safe, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Individuals taking antidepressants may experience personality change, says new report

Individuals taking a medication to treat depression may experience changes in their personality separate from the alleviation of depressive symptoms, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

People who drink may want to know that coffee won't sober them up, according to new laboratory research. Instead, a cup of coffee may make it harder for people to realize they're drunk.

8 Dec 2009

Investigation: Temp firms often employ incompetent nurses

"Firms that supply temporary nurses to the nation's hospitals are taking perilous shortcuts in their screening and supervision, sometimes putting seriously ill patients in the hands of incompetent or impaired caregivers," ProPublica and The Los Angeles Times report. "Emboldened by a chronic nursing shortage and scant regulation, the firms vie for their share of a free-wheeling, $4-billion industry. Some have become havens for nurses who hopscotch from place to place to avoid the consequences of their misconduct."

7 Dec 2009

Regular sexual activity can help improve the overall health in men

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released the top ten reasons regular sexual activity can help improve men’s overall health. From decreased blood pressure to more restful sleep, sexual activity is essential for maintaining bodily functions as well as overall health and well-being.

7 Dec 2009

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

7 Dec 2009

Native Remedies selects TransMedia Group as its PR firm

With more than 500,000 customers worldwide, the market leader in all-natural herbal and homeopathic remedies for people and their pets, Native Remedies, has engaged TransMedia Group as their PR firm of record. The company's two brands, Native Remedies (www.nativeremedies.com) and PetAlive (www.PetAlive.com), provide complete lines of safe, scientifically-tested, guaranteed products that promote health and wellness - naturally.

7 Dec 2009

APU offers tips and suggestions for safe holidays

The 2009 holiday season is officially underway – and while most of us look forward to the fun and excitement, some feel overwhelmed by the stress of office parties, family get-togethers, winter travel and grid-locked shopping mall parking lots.

7 Dec 2009

Children in military families suffer from more emotional difficulties compared to other American youths

Children in military families may suffer from more emotional and behavioral difficulties when compared to other American youths, with older children and girls struggling the most when a parent is deployed overseas, according to a new RAND Corporation study.

7 Dec 2009

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

Anxiety News and Research

Latest Anxiety News and Research

TMZ and small molecule combination appears to lower tumor resistance

The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS children

Veran Medical Technologies' SPiN Drive System receives FDA marketing clearance

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

NeuroPace's RNS System effective for controlling seizures not treatable by medication in epilepsy patients

New NNNS screening tool developed to identify newborn at risk

Young adults with higher blood lead levels more likely to have panic disorders, reveals research

CAM314 randomized Phase 3 clinical trial results released

Individuals taking antidepressants may experience personality change, says new report

Caffeinated energy drink does not neutralize alcohol intoxication, says new study

Investigation: Temp firms often employ incompetent nurses

Regular sexual activity can help improve the overall health in men

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Native Remedies selects TransMedia Group as its PR firm

APU offers tips and suggestions for safe holidays

Children in military families suffer from more emotional difficulties compared to other American youths

Researchers explore optimal induction therapies for managing blood cancer

VELCADE based regimens are cost-effective for payers and patients, finds study

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Anxiety News and Research

Latest Anxiety News and Research

Innovation in neuroscience drug discovery - eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in